2,224
Views
27
CrossRef citations to date
0
Altmetric
Original Research

One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2–4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis

, , , , , , , , , & show all

Reprints and Permissions

Taylor & Francis does not sell reprints or permissions for this article. Please refer to the 'Licensing' tab on the article menu bar for information on the reuse conditions associated with this license type.